ELTX ANGION BIOMEDICA CORP

Elicio Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Elicio Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

BOSTON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that Robert Connelly, Chief Executive Officer, will present at the upcoming Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 13, 2024 at 12:40 PM ET.

A live webcast of the presentation will be accessible under “” in the Investors section of Elicio’s and will be available on-demand for 90 days following the event.

About Elicio Therapeutics

Elicio Therapeutics is a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer. By combining expertise in immunology and immunotherapy, Elicio is engineering investigational Amphiphile (“AMP”) immunotherapies intended to precisely target and fully engage the lymph nodes, the site in our bodies where the immune response is orchestrated. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants and vaccines for an array of aggressive cancers.

Media Contact

Kristin Politi

LifeSci Communications



646-876-4783

Investor Relations Contact

Heather DiVecchia

Elicio Therapeutics



857-209-0153



EN
05/02/2024

Underlying

ELTXANGION BIOMEDICA CORP

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ANGION BIOMEDICA CORP

 PRESS RELEASE
Free
ELTX ANGION BIOMEDIC...

Elicio Therapeutics Reports First Quarter 2025 Financial Results and P...

Elicio Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Updates Interim analysis focused on disease-free survival (“DFS”) in randomized Phase 2 AMPLIFY-7P clinical trial expected in Q3 2025 Company has alignment with U.S. Food and Drug Administration (“FDA”) on key design elements of planned Phase 3 study of ELI-002 Current cash position expected to support operations beyond anticipated AMPLIFY-7P Phase 2 interim analysis BOSTON, May 13, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage b...

May 13, 2025 1 EN
 PRESS RELEASE
Free
ELTX ANGION BIOMEDIC...

Elicio Therapeutics Reports Inducement Grant to New Chief Strategy and...

Elicio Therapeutics Reports Inducement Grant to New Chief Strategy and Financial Officer and Other New Hires BOSTON, April 16, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that on April 15, 2025, Elicio granted inducement awards to Elicio’s newly appointed Chief Strategy and Financial Officer, Preetam Shah, and two additional new employees, as an inducement material to Dr. Shah and such employees enterin...

April 16, 2025 1 EN
 PRESS RELEASE
Free
ELTX ANGION BIOMEDIC...

Elicio Therapeutics Reports 2024 Financial Results and Provides Corpor...

Elicio Therapeutics Reports 2024 Financial Results and Provides Corporate Updates Completed enrollment of Phase 2 AMPLIFY-7P randomized study; disease-free survival (“DFS”) event-driven interim analysis expected in Q3 2025 Aligned with U.S. Food and Drug Administration (“FDA”) on key elements of planned ELI-002 Phase 3 study design, including dose, patient population and primary endpoint analysis Strengthened cash position to support operations beyond the anticipated AMPLIFY-7P Phase 2 interim analysis BOSTON, March 31, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, ...

March 31, 2025 1 EN
 PRESS RELEASE
Free
ELTX ANGION BIOMEDIC...

Elicio Therapeutics Appoints Preetam Shah, Ph.D., MBA, as Chief Strate...

Elicio Therapeutics Appoints Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer BOSTON, March 24, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the appointment of Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer, effective as of the date hereof. Dr. Shah brings a wealth of leadership experience to Elicio after previously serving as chief financial officer, chief business of...

March 24, 2025 1 EN
Jonathan Moreland
  • Jonathan Moreland
Free Trial
SRE SEMPRA ENERGY
PEB Pebblebrook Hot... ... (+24)

InsiderInsights.com Daily Ratings Report: March 7, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

SRE SEMPRA ENERGY
PEB PEBBLEBROOK HOTEL TRUST
PBF PBF ENERGY INC. CLASS A
MTDR MATADOR RESOURCES COMPANY
MPC MARATHON PETROLEUM CORPORATION
LTRX LANTRONIX INC.
FRPT FRESHPET INC
EIX EDISON INTERNATIONAL
DRTTF DIRTT ENVIRONMENTAL SOLUTIONS
CMCO COLUMBUS MCKINNON CORPORATION
FLWS 1-800-FLOWERS.COM CL A
JELD JELD-WEN HOLDING INC.
FRAF FRANKLIN FINANCIAL SERVICES CO.
ELAN ELANCO ANIMAL HEALTH INC.
ABCL ABCELLERA BIOLOGICS
PFBX PEOPLES FINANCIAL CORP. (MISSISSIPPI)
JANX JANUX THERAPEUTICS INC
TNYA TENAYA THERAPEUTICS INC
IE IVANHOE ELECTRIC INC
ECAT BLACKROCK ESG CAP ALLOCATION TR
ELTX ANGION BIOMEDICA CORP
CVI CVR ENERGY
GAM INC.
GENERAL DE ALQUILER DE MAQUINARIA
03/08/25 March 8, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch